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Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin resulting in variable phenotypes 
ranging from severe anemia to clinically asymptomatic individuals. 
Poorly treated patients are presented with growth retardation, 
anemia, icterus, poor weight gain, hepatosplenomegaly, ulcers, 
extramedullary hematopoiesis, and bony changes with bone 
marrow expansion. Repeated transfusion therapy leads to iron 
overload toxicity and systemic complications such as endocrine 
complications (stunting, sexual immaturity, diabetes mellitus, and 
pathology of the parathyroid, thyroid, adrenals, and pituitary), 
cardiomyopathy, and hepatic cirrhosis.
Heart failure secondary to iron overload is the main cause 
of death in patients with thalassemia major. Most of the patients 
suffer from myocardial fibrosis and cardiac dysfunction due to 
an overload of iron in cardiac tissues [1,2]. Iron chelation may 
reduce cardiac iron overload and reduce the rate of mortality 
in such patients. Heart injuries in iron overload cases include 
dilatation of the atria and ventricles, arrhythmia, valvular 
dysfunction, pericarditis, thickening of the muscles, and finally, 
heart failure [2,3]. Although frequent blood transfusion is 
routinely done, patients still suffer from chest pain, tachycardia, 
exhausting, and in some cases, sudden death. To have accurate 
iron chelation, it is necessary to measure the amount of a patient’s 
iron. The most accurate method to measure iron level is liver 
biopsy; however, it is invasive and unable to provide an accurate 
measurement of heart iron level [4].
A great deal of interest has centered on the cardiac function 
that can be evaluated by echocardiography. Some studies 
have proved that serum ferritin cannot show total iron level, 
especially in the heart [5]. On the other hand, some researchers 
have agreed that serum ferritin is associated with the cardiac 
iron level [6]. In addition, they suggested that measurement of 
electrocardiographic parameters is useful methods for better 
evaluation of heart function. Other investigators showed that 
echocardiographic parameters such as ejection fraction (EF), left 
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ventricular end-diastolic diameters (LVEDD), and left ventricular 
end-systolic diameter (LVESD) fractional shortening were 
significantly associated with elevated serum ferritin level. We 
have planned the present study because all the previous studies 
have not derived any cutoff value of serum ferritin for early 
detection of cardiac manifestation.
METHODS
The present observational analytical cross-sectional diagnostic 
study (Phase II) was conducted from November 2016 to 
October 2018 in the Postgraduate Department of Paediatrics, 
of a tertiary care hospital in Burla, after taking approval from 
the institutional ethics committee. The sample size was based 
on correlation coefficient of EF with serum ferritin, i.e. r=0.3 
as per previous study [6]. Sample size was calculated by 
regression correlation coefficient (testing for r=0) method with 
taking the r=0.3, and power of the study to be 90% and α=5%, 
and taking two-sided significance level, minimum sample size 
was calculated to be 104 using nMaster v2 (BRTC, Bagayam, 
Vellore).
Total 123 diagnosed (high-performance liquid chromato-
graphy) cases of multitransfused (received transfusion for >1 year 
and serum ferritin levels >/=1000 ng/ml) [7] beta-thalassemia 
major children between 6 and 14 years of age were screened for 
the inclusion in the study. Out of which, parents of 10 patients did 
not give their consent and 8 were excluded as per the pre-defined 
exclusion criteria. The exclusion criteria were patients with any 
pre-existing congenital heart diseases, rheumatic heart disease or 
any other structural heart defects, and the associated comorbidities 
such as hypertension, dyselectrolytemia, hyperthyroidism, and 
type 1 diabetes mellitus. Finally, 105 beta-thalassemic major 
children were enrolled for the study after taking written informed 
consent from their parents or legal heir by simple consecutive 
sampling technique.
Serum ferritin levels were measured using enzyme-linked 
fluorescent assay by Biomerieux, India. All the patients were 
investigated with two-dimensional echocardiography (as the gold 
standard) in the department of cardiology using the Philips HD11 
model, and the 3 different parameters, namely EF, LVEDD, and 
LVESD, were noted for each of the patients. Normal mean EF is 
66% (range: 56%–78%) [8]. Body surface area was calculated 
using nomogram [9], andbased on this, LVEDD and LVESD in 
mm were recorded.
All the data were collected, validated, and relevant statistical 
analyses such as estimation of sensitivity (Sn), specificity (Sp), 
positive predictive value (PPV), negative predictive value (NPV), 
diagnostic odds ratio (DOR), and likelihood ratios were calculated 
with help of Dxt v1.0 software (BRTC, Bagayam, Vellore). Cutoff 
value of serum ferritin for each of the above three echo parameters 
was calculated by receiver operating characteristic curve analysis 
with SPSS v 24 (IBM, New York) and Dxt v1 software (BRTC, 
Bagayam, Vellore). For all statistical, p<0.05 was considered to 
be statistically significant.
RESULTS
The mean age of the study population was 9.5±3.2 years with 
the mean serum ferritin levels of 3245±1264 ng/ml and mean 
hemoglobin levels of 6.2±1.1 g/dl. In this study, out of 105 
enrolled participants, 9 children were already under chelation 
therapy at the start of the study. The cutoff value of serum ferritin 
was 3261 ng/ml with optimum Sn of 76.1% and Sp of 93.2% 
(Fig. 1) for detecting abnormalities in EF (%) as evident by the 
area under the curve (AUC) of 84.5% (95% confidence interval 
(CI): 75.8–90.9%), p=0.001 and Youden index of 0.693. The 
cutoff value of serum ferritin was 4640 ng/ml with Sn of 68.75% 
and Sp of 100% (Fig. 2) for detecting abnormalities in LVEDD 
(mm) as evidenced by AUC of 79.7% (95% CI: 70.5–87.1%), 
p=0.001 and Youden index of 0.688. The cutoff value of serum 
ferritin was 3261 ng/ml with Sn of 90.0% and Sp of 68.42% 
(Fig. 3) for detecting abnormalities in LVESD (mm) as evidenced 
by AUC of 64.7% (95% CI: 54.1–74.0%), p=0.008 and Youden 
index of 0.584.
Based on these observations, we got the Sn of 76.1% (61.2–
87.4%), Sp of 88.1% (77.1–95.1%), PPV of 83.3% (68.6–
93.0%), NPV of 82.5% (70.9–90.9%), and DOR of 23.6 (8.35–
66.87) to use serum ferritin as an early screening tool for the 
detection of EF abnormalities (Table 1). Similarly, we got 
the Sn of 68.8% (50.0–83.9%), Sp of 98.6% (92.6%–100%), 
PPV of 95.7% (78.1–99.9%), NPV of 87.8% (78.7–94.0%), 
and DOR of 158.4 (19.197–1307.0) to use serum ferritin as 
an early screening tool for detection of LVEDD abnormalities 
(Table 1). For detecting LVESD abnormalities, we got the Sn 
of 90.0% (55.5– 99.7%), Sp of 70.5% (60.3%–79.4%), PPV of 
24.3% (11.8– 41.2%), NPV of 98.5% (92.1–100%), and DOR 
of 21.53 (2.6–178.1) to use serum ferritin as an early screening 
tool (Table 1).
From the above analysis, we have got the highest DOR of 
serum ferritin for detecting LVEDD abnormalities, which mean 
that the efficacy of serum ferritin for early detection of cardiac 
iron overload in terms of LVEDD was the highest, followed by 
Table 1: Different diagnostic accuracy parameters of serum ferritin
Parameters Sn (%) Sp (%) PPV (%) NPV (%) LR+# LR-## (DOR)$
Ser. ferLVEDD* 70.1 98.6 95 86 50.18 0.31 158.4
Ser. ferEF** 76.1 88.1 83 82 6.41 0.27 23.63
Ser. ferLVESD*** 90 70.5 24 98 3.05 0.15 21.5
*Different diagnostic accuracy parameters for serum ferritin levels in detecting cardiac dysfunction when LVEDD is the gold standard. **Different statistical parameters for serum 
ferritin levels in detecting cardiac dysfunction when EF is the gold standard. ***Different statistical parameters for serum ferritin levels in detecting cardiac dysfunction when 
LVESD is the gold standard #Positive Likelihood Ratio, ##Negative Likelihood Rati, $Diagnostic Odd’s ratio. EF: Ejection fraction, LVEDD: Left ventricular end-diastolic diameter, 
LVESD: Left ventricular end-systolic diameter, PPV: Positive predictive value, NPV: Negative predictive value, DOR: Diagnostic odds ratio
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approximately same for EF and LVESD. The diagnostic accuracy 
was increased by 50 times if serum ferritin was used for detecting 
LVEDD abnormalities, but the accuracy decreases significantly if 
it was done for assessing EF and LVESD abnormalities.
DISCUSSION
The serum ferritin level is not specific for iron overload and may 
increase in many clinical conditions, including inflammation, 
liver disease, collagen tissue disease, and malignancy [11]. 
Moreover, a low serum ferritin level is not associated with a 
reduction in the risk of iron-induced cardiomyopathy [10]. 
Quick and easy detection of myocardial iron overload is crucial 
for detection of cardiac failure and its early management [12]. 
Proper treatment and early chelation therapy will lead to the early 
remediation [12,13]. In non-chelated patients receiving regular 
transfusions, cardiomegaly develops by the age of 10 years 
and heart failure by the age of 16 years [14]. Iron overload in 
thalassemia major (TM) occurs due to a combination of frequent 
blood transfusions and excessive gastrointestinal absorption 
[15]. Little is known about the natural history of iron deposition 
in the heart. Previous studies acknowledged that serum ferritin 
levels were higher in beta-thalassemia patients who had received 
more than 50 transfusions [16]. There are studies suggesting 
that myocardial deposition takes place after a minimum of 
75 blood transfusions [15,16]. In one study of 110 patients 
echocardiographic abnormalities were found in patients with 
less than 50 transfusions [17]. Assessment of myocardial iron is 
essential clinically.
In another earlier reports, it was suggested that cardiac iron 
overload occurred only after at least 13 years of chronic transfusion 
therapy [18]. Serum ferritin level has been used as the most 
common predictor of iron overload in TM [19]. Echocardiography 
is useful to study anatomical changes of the heart; however, 
functional changes are usually observed in advanced stages of 
cardiomyopathy [20]. In one study, echocardiographic parameters 
such as the difference of pulmonary vein-atrial reversal flow 
and mitral valve A (PVAR-MVA) wave duration [21] and early 
ventricular filling velocity to early diastolic myocardial velocity 
ratio (E/Em) were found to be significantly correlating with the 
serum ferritin with abnormality being detected in values >5000 ng/
ml and normal values <2500 ng/ml, but single correlating cutoff 
value was lacking which could have provided a diagnostic value. 
These studies, however, were based on well-chelated patients. 
Fernandes et al. recently reported a single patient with cardiac 
iron overload at the age of 7 years, but this study was limited to 
only 23 patients with TM and other forms of anemia [21].
In a case–control study conducted in Mumbai in 2008–2009, 
60 cases were evaluated for cardiac iron overload toxicity 
through cardiac magnetic resonance imaging (MRI), in which 
the mean value of serum ferritin was found to be 3528.6±1958.6 
ng/ml and it had significant difference in the mean cardiac MRI 
T2* values (23.45±13.4 ms) when  compared with the controls 
(32.67±2.68 ms) with p<0.01 [22]. In the present study, we have used 
echocardiographic parameters such as LVEDD, EF, and LVESD 
and also measured serum ferritin levels in 105 β-thalassemia major 
children. All TM kids with serum ferritin >3000 ng/ml (cutoff value 
being 3261 ng/ml for EF and LVESD and 4640 ng/ml for LVEDD) 
should be investigated with echocardiography to screen for cardiac 
dysfunction due to iron overload and toxicity.
Figure 1: Receiver operating characteristic curve of serum ferritin 
for detecting abnormality in ejection fraction
Figure 2: Receiver operating characteristic curve of serum ferritin 
for detecting abnormality in left ventricular end-diastolic diameter
Figure 3: Receiver operating characteristic curve of serum ferritin 
for detecting abnormality in left ventricular end-systolic diameter
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We note that again LVEDD has the highest PPV along with a 
good NPV. It signifies that it has got a good and reliable testing 
power in establishing the pre-clinical cardiac dysfunction due to 
iron overload based on the strength of serum ferritin values as a 
guide. The parameters in this regard were ordered as: LVEDD >> 
EF > LVESD with the Sn of 90%, 76%, and 70%, respectively. 
Serum ferritin is a reliable screening tool to detect cardiac iron 
overload through the echo parameters well before the clinical 
features have appeared.
This study has also some limitations. First of all, we have 
conducted a Phase II study, where we have only found the 
association but causality of the diagnostic accuracy could not be 
assessed. Biases and confounding factor were adjusted as far as 
possible but could not be avoided fully due to the study design 
per se. Hence, a follow-up study would be a better option, where 
we can assess a definite causality for diagnostic accuracy. Second, 
the less sample size of our study is another pitfall. Hence, in the 
future, a diagnostic study of Phase III and/or more should be done 
to reach a definite diagnostic accuracy.
CONCLUSION
This study is one of its kinds as it ensures a cutoff value for serum 
ferritin for diagnosing pre-clinical cardiac dysfunction due to iron 
overload through specific reliable echo parameters. Hence, health-
care personnel can easily scrutinize for cardiac dysfunction, well 
before the clinical features of cardiac iron overload appears and 
hence, it helps to control and prevent morbidity and mortality, 
early. It has a role in improving survival rates by decreasing 
the morbidity and mortality due to iron overload toxicity beta-
thalassemic children.
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